Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 8/2017

01-08-2017 | Original Contributions

Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients

Authors: Rafael Bergesch D’Incao, Cristiane Valle Tovo, Vanessa Suñé Mattevi, Diego Olschowsky Borges, Jane Maria Ulbrich, Gabriela Perdomo Coral, Mauricio Jacques Ramos, Nelson Guardiola Meinhardt

Published in: Obesity Surgery | Issue 8/2017

Login to get access

Abstract

Background

Obesity is a worldwide prevalent disease and is an underlying factor of non-alcoholic fatty liver disease (NAFLD). It has been understood as a chronic inflammatory state, being associated with the production of adipokines. The aim of this study was to analyze the levels of adipokines in the serum, visceral, and subcutaneous fat and to compare them with hepatic histopathology in morbidly obese patients.

Methods

This is a cross-sectional observational study, which analyzed the findings of liver biopsy in patients undergoing bariatric surgery and who had performed analysis of adipokines mRNA expression (adiponectin—ADIPOQ, leptin—LEP, and resistin—RETN) in subcutaneous and visceral adipose tissue and circulating adipokines in serum. Liver biopsies performed were evaluated according to Kleiner criteria.

Results

The study analyzed 25 patients undergoing bariatric surgery. The sample was composed exclusively of women. There was a predominance of NAFLD, with 21 patients (84%) with intrahepatic fat accumulation. Twelve patients presented non-alcoholic steatohepatitis (NASH). Glycated hemoglobin levels (HbA1c) were elevated in NASH patients. ADIPOQ levels were directly correlated with high-density lipoprotein (HDL) cholesterol levels and inversely correlated with triglycerides and total cholesterol. LEP levels showed an inverse relationship with the degree of steatosis, and RETN levels showed an inverse relationship with fibrosis stages.

Conclusion

Serum LEP levels were reduced in the presence of increased levels of intrahepatic fat, and serum levels of RETN were diminished in the presence of NASH. HbA1c levels were higher in the presence of NASH, indirectly reflecting insulin resistance. Moreover, ADIPOQ levels were related to blood lipid profile.
Literature
1.
Lau DCW, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. Can Med Assoc J. 2007;176(8):S1–13.CrossRef
2.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.CrossRefPubMed
3.
WGO Global Guidelines. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterol Organ Guidel. 2012.
4.
Losekann A, Weston A, de Mattos A, et al. Non-alcoholic steatohepatitis (NASH): risk factors in morbidly obese patients. Int J Mol Sci. 2015;16(10):25552–9.CrossRefPubMedPubMedCentral
5.
Losekann A, Weston AC, Carli LA, et al. Nonalcoholic fatty liver disease in severe obese patients, subjected to bariatric surgery. Arq Gastroenterol. 2013;50(4):285–9.CrossRefPubMed
6.
Rinella ME. Nonalcoholic fatty liver disease a systematic review. JAMA. 2015;169(2):170.
7.
Frayn KN, Arner P, Yki-Jarvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem. 2006;42:89–103.CrossRefPubMed
8.
Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:1–25.CrossRef
9.
Petta S, Gastaldelli A, Rebelos E, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci. 2016;17(12):2082.CrossRefPubMedCentral
10.
Li X-L, Sui J-Q, Lu L-L, et al. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis Lipids in Health and Disease. 2016;15(1):53.CrossRefPubMed
11.
Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27(5):412–21.CrossRefPubMed
12.
Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials. 2014;9(3):134–40.CrossRefPubMed
13.
Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17(23):2801–11.PubMedPubMedCentral
14.
Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(48):18070–91.CrossRefPubMedPubMedCentral
15.
Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediat Inflamm. 2009;2009:831670.CrossRef
16.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed
17.
Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol. 2006;64(6):679–83.CrossRef
18.
Karbowska J, Kochan Z. Role of adiponectin in the regulation of carbohydrate and lipid metabolism. In: J Physiol Pharmacol. 2006. p. 103–13.
19.
Lee B, Shao J. Adiponectin and lipid metabolism in skeletal muscle. Acta Pharm Sin B. 2012;2(4):335–40.CrossRef
20.
Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. In: J Clin Endocrinol Metabol. 2004. p. 2665–71.
21.
Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90(6):3498–504.CrossRefPubMed
22.
Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152(1):113–8.CrossRefPubMed
23.
Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism. 2016;65(9):1297–306.CrossRefPubMed
24.
Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226–8.CrossRefPubMed
25.
Argentou M, Tiniakos DG, Karanikolas M, et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19(9):1313–23.CrossRefPubMed
26.
Abenavoli L, DI Renzo L, Guzzi PH, et al. Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship. Clujul Med. 2015;88(4):489–93.CrossRefPubMedPubMedCentral
27.
Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16(9):1118–25.CrossRefPubMed
28.
Jamali R, Arj A, Razavizade M, et al. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine (Baltimore). 2016a;95(5):e2630.CrossRef
29.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–5.CrossRefPubMed
30.
Lönnqvist F, Arner P, Nordfors L, et al. Overexpression of the obese (Ob) gene in adipose tissue of human obese subjects. Nat Med. 1995;1(9):950–3.CrossRefPubMed
31.
Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101(11):2629–40.CrossRefPubMed
32.
Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122(5):1399–410.CrossRefPubMed
33.
Ikejima K, Honda H, Yoshikawa M, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34(2):288–97.CrossRefPubMed
34.
Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36(2):403–9.CrossRefPubMed
35.
Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;43(9):1128–36.CrossRefPubMed
36.
Polyzos SA, Aronis KN, Kountouras J, et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30–43.CrossRefPubMed
37.
Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metab Clin Exp. 2015;64:60–78.CrossRefPubMed
38.
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12.CrossRefPubMed
39.
De Luis DA, Terroba MC, Cuellar L, et al. Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res. 2011;43(3):205–8.CrossRefPubMed
40.
Aller R, de Luis D, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci. 2008;53(4):1088–92.CrossRefPubMed
41.
Pagano C, Soardo G, Pilon C, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006;91(3):1081–6.CrossRefPubMed
42.
Senates E, Çolak Y, Yesil A, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and its associated with steatosis, portal inflammation, insulin resistance and no alcoholic steatohepatitis scores. Minerva Med. 2012;53(9):1689–99.
43.
Cengiz C, Ardicoglu Y, Bulut S, et al. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis? Eur J Gastroenterol Hepatol. 2010;22(7):813–9.CrossRefPubMed
44.
Jamali R, Razavizade M, Arj A, et al. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol. 2016b;22(21):5096–103.CrossRefPubMedPubMedCentral
45.
Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab. 2006;91(12):5122–5.CrossRefPubMed
46.
Bekaert M, Verhelst X, Geerts A, et al. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17(1):68–80.CrossRefPubMed
47.
Samaras K, Botelho NK, Chisholm DJ, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (silver spring). Nat Publ Group. 2010;18(5):884–9.
48.
Blüher M, Fasshauer M, Kralisch S, et al. Regulation of adiponectin receptor R1 and R2 gene expression in adipocytes of C57BL/6 mice. Biochem Biophys Res Commun. 2005;329(3):1127–32.CrossRefPubMed
Metadata
Title
Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients
Authors
Rafael Bergesch D’Incao
Cristiane Valle Tovo
Vanessa Suñé Mattevi
Diego Olschowsky Borges
Jane Maria Ulbrich
Gabriela Perdomo Coral
Mauricio Jacques Ramos
Nelson Guardiola Meinhardt
Publication date
01-08-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 8/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-017-2627-4

Other articles of this Issue 8/2017

Obesity Surgery 8/2017 Go to the issue

Letter to Editor/LED Reply

Reply to Comment on “The Impact of Psychological Support on Weight Loss Post Weight Loss Surgery: a Randomised Control Trial” Ratcliffe et al.

Original Contributions

Robotic Gastric Bypass Surgery in the Swiss Health Care System: Analysis of Hospital Costs and Reimbursement

Original Contributions

Predictors of Physical Activity After Gastric Bypass—a Prospective Study

Letter to the Editor

Outcomes of Bariatric Surgery in Patients with Inflammatory Bowel Disease

Original Contributions

Vertical Gastric Bypass with Fundectomy: Feasibility and 2-Year Follow-Up in a Series of Morbidly Obese Patients

Original Contributions

Intra-thoracic Sleeve Migration (ITSM): an Underreported Phenomenon After Laparoscopic Sleeve Gastrectomy